Fructus Corni Officinalis water extract Ameliorates Memory Impairment and Beta amyloid (Aβ) clearance by LRP-1 Expression in the Hippocampus of a Rat model of Alzheimer’s Disease
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study evaluated the effects of Fructus Corni Officinalis water extract (FCE) on congnitive impairment and Aβ clearance induced by beta amyloid Aβ (1-42) injection in the hippocampus of rat. Aβ (1-42) was injected into the hippocampus using a Hamilton syringe and micropump (5 ㎍/5 ㎕, 1 ㎕/min, each hippocampus bilaterally). FCE was administered orally once a day (100, 250, 500 mg/kg) for 4 weeks after the Aβ (1-42) injection. The acquisition of learning and retention of memory were tested using the Morris water maze. Aβ accumulation and Aβ clearance in the hippocampus were observed using immunostaining. Aβ (1-42) level in plasma was confirmed using enzyme-linked immunosorbent assay (ELISA). FCE significantly shortened the escape latencies during acquisition training trials. FCE significantly increased the number of target heading to the platform site and significantly shortened the time for the 1sttargetheadingduringtheretentiontesttrial.FCEsignificantlyattenuatedtheAβ accumulation in the hippocampus produced by Aβ (1-42) injection. FCE significantly increased LRP-1 expression around vessels in the hippocampus and Aβ (1-42) levels in plasma. The results suggest that FCE improved cognitive impairment by ameliorate Aβ clearance and Aβ accumulation in the hippocampus. FCE may be a beneficial herbal formulation in treating cognitive impairment including Alzheimer’s disease.
Abstract
This study evaluated the effects of Fructus Corni Officinalis water extract (FCE) on congnitive impairment and Aβ clearance induced by beta amyloid Aβ (1-42) injection in the hippocampus of rat. Aβ (1-42) was injected into the hippocampus using a Hamilton syringe and micropump (5 ㎍/5 ㎕, 1 ㎕/min, each hippocampus bilaterally). FCE was administered orally once a day (100, 250, 500 mg/kg) for 4 weeks after the Aβ (1-42) injection. The acquisition of learning and retention of memory were tested using the Morris water maze. Aβ accumulation and Aβ clearance in the hippocampus were observed using immunostaining. Aβ (1-42) level in plasma was confirmed using enzyme-linked immunosorbent assay (ELISA). FCE significantly shortened the escape latencies during acquisition training trials. FCE significantly increased the number of target heading to the platform site and significantly shortened the time for the 1sttargetheadingduringtheretentiontesttrial.FCEsignificantlyattenuatedtheAβ accumulation in the hippocampus produced by Aβ (1-42) injection. FCE significantly increased LRP-1 expression around vessels in the hippocampus and Aβ (1-42) levels in plasma. The results suggest that FCE improved cognitive impairment by ameliorate Aβ clearance and Aβ accumulation in the hippocampus. FCE may be a beneficial herbal formulation in treating cognitive impairment including Alzheimer’s disease.
참고문헌 (37)
- Blennow, K., "Alzheimer’s disease", Lancet, 368(9533), pp.387~403 (2006)
- Dickson, D. W., "The pathogenesis of senile plaques", J Neuropathol Exp Neurol, 56(4), pp.321~339 (1997)
- Yates, S. L., "Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia", J Neurochem, 74(3), pp.1017~1025 (2000)
- Selkoe, D. J., "Alzheimer’s disease: Molecular understanding predicts amyloid-based therapeutics", Annu Rev Pharmacol Toxicol, 43, pp.545~584 (2003)
- Liu, H., "Regulation of β-amyloid level in the brain of rats with cerebrovascular hypoperfusion", Neurobiol Aging, 33(826), pp.31~42 (2012)
- Wang, Y. J., "Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives", Drug Discov Today, 11(20), pp.931~938 (2006)
- Donahue, J. E., "RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease", Acta Neuropathol, 112(4), pp.405~415 (2006)
- Scripnikov, A., "GINDEM-NP Study Group. Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial", Wien Med Wochenschr, 157(13), pp.295~300 (2007)
- Han, Y., "Selective therapeutic effect of cornus officinalis fruits on the damage of different organs in STZ-induced diabetic rats", Am J Chin Med, 42(5), pp.1169~1182 (2014)
- Jeong, E. J., "Neuroprotective iridoid glycosides from Cornus officinalis fruits against glutamate-induced toxicity in HT22 hippocampal cells", Phytomedicine, 15(19), pp.317~321 (2012)
- Wang, W., "Morroniside protects human neuroblastoma SH-SY5Y cells against hydrogen peroxide-induced cytotoxicity", Eur J Pharmacol, 24(613), pp.19~23 (2009)
- Hong, S. Y., "Protective effects of the key compounds isolated from Corni fructus against β-amyloid-induced neurotoxicity in PC12 cells", Molecules, 10(17), pp.10831~10845 (2012)
- Blennow, K., "Alzheimer's disease", Lancet, 368(9533), pp.387~403 (2006)
- Dickson, D.W., "The pathogenesis of senile plaques", J Neuropathol Exp Neurol, 56(4), pp.321~339 (1997)
- Grundke-Iqbal, I., "Microtubule-associated protein tau. A component of alzheimer paired helical filaments", J Biol Chem, 261(13), pp.6084~6089 (1986)
- Ball, M. J., "Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study", Acta Neuropathol, 37(2), pp.111~118 (1977)
- Kuhl, D. E., "In vivo mapping of cerebral acetylcholinesterase activity in aging and alzheimer's disease", Neurology, 52(4), pp.691~699 (1999)
- Selkoe, D. J., "Amyloid beta-protein and the genetics of alzheimer's disease", J Biol Chem, 271(31), pp.18295~19298 (1996)
- Cacquevel, M., "Cytokines in neuroinflammation and alzheimer's disease", Curr Drug Targets, 5(6), pp.529~534 (2004)
- Berezovska, O., "Familial alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein", J Neurosci, 25(11), pp.3009~3017 (2005)
- Mhatre, M., "Oxidative stress and neuroinflammation in alzheimer's disease and amyotrophic lateral sclerosis: Common links and potential therapeutic targets", J Alzheimers Dis, 6(2), pp.147~157 (2004)
- Roberson, M. R., "Cholinergic denervation and sympathetic ingrowth result in persistent changes in hippocampal muscarinic receptors", Neuroscience, 80(2), pp.413~418 (1997)
- De Ferrari, G. V., "A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation", Biochemistry, 40(35), pp.10447~10457 (2001)
- Deane, R., "Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease", CNS & neurological disorders drug targets, 8(1), pp.16~30 (2009)
- Ramanathan, A., "Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer’s disease: The role, regulation and restoration of LRP1", Frontiers in Aging Neuroscience, 7, pp.136~ (2015)
- Bell, R. D., "Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system", J Cereb Blood Flow Metab, 27, pp.909~918 (2007)
- Deane, R., "LRP", amyloid beta-peptide interaction mediates differential brain efflux of Aβ isoforms, 2004, pp.43, 333~344
- 이기용, "Cognitive-enhancing Activity of Loganin Isolated from Cornus officinalis in Scopolamine-induced Amnesic Mice", Archives of Pharmacal Research, 32(5), pp.677~683 (2009), 대한약학회
- Rui Wang, "Resveratrol ameliorates spatial learning memory impairment induced by Aβ1–42 in rats", Neuroscience (2016), Elsevier BV[DOI]
- Ashabi, G., "Reduction of hippocampal apoptosis by intracerebroventricular administration of extracellular signal-regulated protein kinase and", or p38 inhibitors in amyloid beta rat model of Alzheimer's disease: involvement of nuclear-related factor-2 and nuclear factor-κB, 2013, pp.112(3), 145~155
- Lecanu, L., "Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain", Pharmacology, 76, pp.19~33 (2006)
- Kamenetz, F., "APP processing and synaptic function", Neuron, 37, pp.925~937 (2003)
- Donahue, J. E., "RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease", Acta Neuropathol, 112(4), pp.405~415 (2006)
- Shibata, M., "Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier", J Clin Invest, 106, pp.1489~1499 (2000)
- Tamaki, C., "Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver", Pharm. Res., 23, pp.1407~1416 (2006)
- Bell, R. D., "Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system", J. Cereb. Blood Flow Metab, 27, pp.909~918 (2007)
- Sagare, A., "Clearance of amyloid-beta by circulating lipoprotein receptors", Nat. Med., 13, pp.1029~1031 (2007)